Physician

Jason L. Blaser, MD

According to 2025 Medicare claims, Jason Blaser, MD (NPI: 1265477681) practices dermatology in the Tyler, TX market, with the plurality of this provider's patient population coming from Smith, TX. This provider's primary affiliated billing organization is EPIPHANY DERMATOLOGY PA (NPI: 1043615263; TIN: 47-2190514) and primary practice location at 75701-2044.

Blaser's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 720 traditional Medicare patients, billed 7,025 HCPCS/CPT codes, and received $431,417 in Medicare payments. The top billing code was 11102 (Biopsy of related skin growth, first growth). Part D data shows 660 prescription claims across 341 beneficiaries totaling $609,446 in drug costs, led by Skyrizi Pen (Risankizumab-Rzaa). Open Payments data shows 33 records totaling $512. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $620,890 to $431,417. In contrast, Part D prescription costs have moved from a lower plateau to a higher plateau, from $74,983 to $609,446. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$356K$713K2015 Medicare payment: $620,890 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $711,992 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $567,829 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $670,000 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $712,830 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $531,321 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $544,187 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $293,381 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $555,429 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $431,417 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
20152,34911,621$620,890
20162,37412,306$711,992
20171,99010,289$567,829
20181,08217,374$670,000
201999012,355$712,830
20208508,962$531,321
202176911,255$544,187
20225454,852$293,381
20237318,807$555,429
20247207,025$431,417

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$305K$609K2015 Drug cost: $74,983 (USD; Tot_Drug_Cst)2016 Drug cost: $90,908 (USD; Tot_Drug_Cst)2017 Drug cost: $110,762 (USD; Tot_Drug_Cst)2018 Drug cost: $157,926 (USD; Tot_Drug_Cst)2019 Drug cost: $262,578 (USD; Tot_Drug_Cst)2020 Drug cost: $370,150 (USD; Tot_Drug_Cst)2021 Drug cost: $441,522 (USD; Tot_Drug_Cst)2022 Drug cost: $280,273 (USD; Tot_Drug_Cst)2023 Drug cost: $372,423 (USD; Tot_Drug_Cst)2024 Drug cost: $609,446 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015382849$74,983
2016361858$90,908
2017325793$110,762
20184301,145$157,926
2019393946$262,578
2020310680$370,150
2021291613$441,522
2022162284$280,273
2023309628$372,423
2024341660$609,446

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
11102Biopsy of related skin growth, first growth299384$65
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more456709$58
17000Destruction of precancer skin growth, 1 growth377601$35
88305Pathology examination of tissue using a microscope, intermediate complexity458922$26
17003Destruction of precancer skin growth, 2-14 growths3172,241$5

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Skyrizi PenRisankizumab-Rzaa13980$264,058
OtezlaApremilast12360$57,890
FluorouracilFluorouracil381,078$2,797
FluocinonideFluocinonide651,994$1,966
TacrolimusTacrolimus11286$1,690

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.33$512ABBVIE INC.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Jason L. Blaser, MD?

Tedicare shows public-source Medicare data for Jason L. Blaser, MD (NPI 1265477681), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jason L. Blaser, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Jason L. Blaser, MD?

Jason L. Blaser, MD is linked to EPIPHANY DERMATOLOGY PA (billing NPI 1043615263) in the available physician profile data.

Does Jason L. Blaser, MD have Open Payments data?

Jason L. Blaser, MD has 33 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.